Weisen Selected as "Global IP Star Company"... Strengthening Position in AI Endoscopy Sector

Integrating Patent Strategies from the R&D Stage

Weisen, an artificial intelligence (AI) medtech company, announced on April 20 that it has been selected as a "2026 Global IP Star Company" by the Korean Intellectual Property Office.

Medical staff using Wecen's AI endoscopy solution 'Wemed Endo'. Wecen

Through this selection, Weisen has been officially recognized for its technological competitiveness in the AI endoscopy sector and its growth potential in the global market. The company plans to further strengthen its strategy for securing overseas patents and expanding into global markets.

The Global IP Star Company Development Program is organized by the Korean Intellectual Property Office and regional intellectual property centers to identify promising small and medium-sized enterprises (SMEs) with strong export potential and provide them with systematic, comprehensive intellectual property (IP) support for three years. The goal is to nurture these companies into global hidden champions through tailored support for each company.

Weisen has enhanced its technological competitiveness by securing numerous key patents both in Korea and overseas, centered around its AI endoscopy solution, "WAYMED ENDO." In particular, the company has pursued a proactive IP strategy, systematically building its IP portfolio as a core strategy for global market leadership and integrating patent strategies from the early stages of research and development.

WAYMED ENDO is a medical AI software that detects abnormal lesions in real time and classifies their characteristics during gastric and colon endoscopy procedures. Its key feature is the ability to detect even subtle or easily missed lesions, thereby improving diagnostic accuracy for medical staff and standardizing the quality of examinations at a higher level. According to the company, it has already begun generating significant sales overseas and continues to expand brand recognition not only in Southeast Asian countries, including Vietnam and Thailand, but also in the Middle East region.

A Weisen representative stated, "Being selected as a Global IP Star Company is recognition not only of Weisen's AI endoscopy technology but also of our global expansion strategy based on intellectual property. We will continue to enhance our IP competitiveness and establish a leading position in the global AI endoscopy market, with WAYMED ENDO at the center of our efforts."

This content was produced with the assistance of AI translation services.